Botulinum Toxin Market Scope And Analysis

Report Code : TIPRE00027431
Category : Life Sciences

Status : Published
No. of Pages : 381

Buy Now

Botulinum Toxin Market Scope and Analysis Report by 2031

Buy Now

Botulinum Toxin Market Report Scope

Report Attribute	Details
Market size in 2023	US$ 7.38 Billion
Market Size by 2031	US$ 19.03 Billion
Global CAGR (2023 - 2031)	12.6%
Historical Data	2021-2022
Forecast period	2024-2031
Segments Covered	By Product Botulinum Toxin A Botulinum Toxin B By Application Medical Aesthetic By End User Speciality and Dermatology Clinics Hospitals and Clinics
Regions and Countries Covered	North America US Canada Mexico Europe UK Germany France Russia Italy Rest of Europe Asia-Pacific China India Japan Australia Rest of Asia-Pacific South and Central America Brazil Argentina Rest of South and Central America Middle East and Africa South Africa Saudi Arabia UAE Rest of Middle East and Africa
Market leaders and key company profiles	AbbVie Inc Merz Pharma Medytox Ipsen Pharma Galderma Revance Therapeutics Inc Lanzhou Institute of Biological Products Co Ltd Evolus Inc Hugel Inc Aquavit

Competitive Landscape and Key Companies:

The botulinum toxin market forecast can help stakeholders in this marketplace plan their growth strategies. AbbVie Inc., Merz Pharma, Medytox, Ipsen Pharma, Galderma, Revance Therapeutics Inc., Lanzhou Institute of Biological Products Co Ltd, Evolus Inc, Hugel Inc, and Aquavit are among the prominent companies profiled in the botulinum toxin market report. These companies focus on developing new technologies, upgrading existing products, and expanding their geographic presence to meet the growing consumer demand worldwide. As per company press releases, below are a few recent developments:

In January 2024, Medytox, Inc. announced the formation of Luvantas, Inc. as its wholly owned North American subsidiary. Luvantas is a new medical aesthetics company committed to bringing innovative solutions to the North American market. It is working with Medytox to seek approval for its upcoming NivobotulinumtoxinA to introduce it into the US and Canada.
In March 2024, Hugel, a medical aesthetics company, received US FDA approval for Letybo injection (letibotulinumtoxinA-wlbg) for the treatment of Glabellar Lines.
In October 2022, Hugel resubmitted the Biologics License Application (BLA) to the US FDA for its botulinum toxin called Botulax for the treatment of glabellar lines. Hugel received a Complete Response Letter (CRL) from the US FDA in March 2022 after submitting the BLA for Botulax (50 and 100 units) to advance into the US market. The company sent supplemental documents and data based on requests set out in the CRL and resubmitted the BLA to the US FDA. After the approval, Hugel entered into the US market in the first half of 2023.
In February 2022, Merz Therapeutics invested up to US$ 3 million to expand its strategic partnership with Vensica Therapeutics, Israel. This investment followed the strategic license and collaboration agreement signed in 2021. Merz thus executed its contractual agreement to participate in Vensica’s Series C financing round and invest in the start-up.